Stroke-Related Sarcopenia: Pathophysiology and Diagnostic Tools
- PMID: 39649713
- PMCID: PMC11621676
- DOI: 10.12786/bn.2024.17.e23
Stroke-Related Sarcopenia: Pathophysiology and Diagnostic Tools
Abstract
Sarcopenia is characterized by the progressive loss of muscle mass and strength and can be categorized as either primary or secondary. Patients who have experienced a stroke may develop sarcopenia, which can adversely impact their functional recovery. The pathophysiology of sarcopenia related to stroke involves nutritional deficiency, disuse atrophy, denervation, and metabolic disturbance. Various evaluation tools are available to diagnose this condition, assessing skeletal muscle mass, muscle strength, and physical function. However, due to the limitations of traditional sarcopenia diagnostic criteria in the context of stroke, there is pressing need to establish diagnostic standards that accurately reflect the disabilities experienced by patients with stroke.
Keywords: Diagnosis; Pathophysiology; Sarcopenia; Stroke.
Copyright © 2024. Korean Society for Neurorehabilitation.
Conflict of interest statement
Conflict of Interest: The authors have no potential conflicts of interest to disclose.
Figures

References
-
- Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G, Andrieu S, Bauer J, Breuille D, Cederholm T, Chandler J, De Meynard C, Donini L, Harris T, Kannt A, Keime Guibert F, Onder G, Papanicolaou D, Rolland Y, Rooks D, Sieber C, Souhami E, Verlaan S, Zamboni M. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12:249–256. - PMC - PubMed
-
- Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, Kojima T, Kuzuya M, Lee JSW, Lee SY, Lee WJ, Lee Y, Liang CK, Lim JY, Lim WS, Peng LN, Sugimoto K, Tanaka T, Won CW, Yamada M, Zhang T, Akishita M, Arai H. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21:300–307.e2. - PubMed
-
- Steindl A, Leitner J, Schwarz M, Nenning KH, Asenbaum U, Mayer S, Woitek R, Weber M, Schöpf V, Berghoff AS, Berger T, Widhalm G, Prayer D, Preusser M, Furtner J. Sarcopenia in neurological patients: standard values for temporal muscle thickness and muscle strength evaluation. J Clin Med. 2020;9:1272. - PMC - PubMed
-
- Leitner J, Pelster S, Schöpf V, Berghoff AS, Woitek R, Asenbaum U, Nenning KH, Widhalm G, Kiesel B, Gatterbauer B, Dieckmann K, Birner P, Prayer D, Preusser M, Furtner J. High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases. PLoS One. 2018;13:e0207849. - PMC - PubMed
-
- Furtner J, Berghoff AS, Schöpf V, Reumann R, Pascher B, Woitek R, Asenbaum U, Pelster S, Leitner J, Widhalm G, Gatterbauer B, Dieckmann K, Höller C, Prayer D, Preusser M. Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases. J Neurooncol. 2018;140:173–178. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources